SK Bioscience Readies $1.3bn IPO Amid Rosy Vaccine Outlook

Expects Continued Rise In COVID-19 Vaccine Demand

 
• By Jung Won Shin
Jae-Yong Ahn, CEO of SK Bioscience
SK Says Its “Unrivaled” In Asia In COVID-19 Vaccine Manufacturing, Development • Source: SK Bioscience

More from COVID-19

More from Scrip